Cardiac T2 Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major von KIRK, P, ROUGHTON, M, PENNELL, D. J, PORTER, J. B, WALKER, J. M, TANNER, M. A, PATEL, J, WU, D, TAYLOR, J, WESTWOOD, M. A, ANDERSON, L. J

Volltext

P-183 Gastrointestinal disturbances in iron-overloaded myelodysplastic syndromes patients receiving concomitant medications during deferasirox treatment von Gattermann, N, Porter, J.B, Rose, C, Schmid, M, Vassilieff, D, Guerci-Bresler, A, Ganser, A, Taylor, K, Louw, V.J, El-Ali, A, Martin, N, Cappellini, M.D

Volltext

Quality of life in thalassemia: A comparison of SF‐36 results from the thalassemia longitudinal cohort to reported literature and the US norms von Sobota, A., Yamashita, R., Xu, Y., Trachtenberg, F., Kohlbry, P., Kleinert, D.A., Giardina, P.J., Kwiatkowski, J.L., Foote, D., Thayalasuthan, V., Porter, J.B., Thompson, A.A., Schilling, L., Quinn, C.T., Neufeld, E.J.

Volltext

S1632 SAFETY AND EFFICACY OF LENTIGLOBIN GENE THERAPY IN PATIENTS WITH TRANSFUSION‐DEPENDENT B‐THALASSAEMIA AND NON‐B0/B0 GENOTYPES IN THE PHASE 3 NORTHSTAR‐2 STUDY von Locatelli, F., Thompson, A.A., Hongeng, S., Porter, J.B., Sauer, M.G., Kwiatkowski, J.L., Thrasher, A.J., Thuret, I., Elliot, H., Tao, G., Colvin, R.A., Walters, M.C.

Volltext

S140 RESULTS FROM THE PHASE 3 NORTHSTAR‐3 STUDY EVALUATING LENTIGLOBIN GENE THERAPY IN PATIENTS WITH TRANSFUSION‐DEPENDENT β‐THALASSAEMIA AND A β0 OR IVS‐I‐110 MUTATION AT BOTH ALL... von Kulozik, A.E., Locatelli, F., Yannaki, E., Porter, J.B., Thuret, I., Sauer, M.G., Lal, A., Kwiatkowski, J.L., Elliot, H., Tao, G., Colvin, R.A., Thompson, A.A.

Volltext

Recent Insights into Interactions of Deferoxamine with Cellular and Plasma Iron Pools: Implications for Clinical Use von PORTER, J.B., RAFIQUE, R., SRICHAIRATANAKOOL, S., DAVIS, B. A., SHAH, F. T., HAIR, T., EVANS, P.

Volltext

Monitoring and treatment of iron overload: State of the art and new approaches von Porter, J.B.

Volltext

Kinetics of Removal and Reappearance of Non-Transferrin-Bound Plasma Iron With Deferoxamine Therapy von Porter, J.B., Abeysinghe, R.D., Marshall, L., Hider, R.C., Singh, S.

Volltext

Long-Term Effects of Deferasirox (Exjade®, ICL670) on Serum Ferritin: Outcome of Dose Adjustments in Achieving Maintenance or Reduction in Body Iron Stores von Porter, J.B., Cohen, A., Agaoglu, L., Ganser, A., Cappellini, M.D., Maseruka, H., Glimm, E., Alberti, D.

Volltext

Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease : A pilot study von SULAIMAN SHOAB, S, PORTER, J. B, SCURR, J. H, COLERIDGE-SMITH, P. D

Volltext

Why Are Hemoglobin F Levels Increased in HbE/β Thalassemia? von Rees, D.C., Porter, J.B., Clegg, J.B., Weatherall, D.J.

Volltext

Endothelial activation in patients with chronic venous disease von Saharay, M., Shields, D.A., Georgiannos, S.N., Porter, J.B., Scurr, J.H., Coleridge Smith, P.D.

Volltext

Why Are Hemoglobin F Levels Increased in HbE/β Thalassemia? von Rees, D.C., Porter, J.B., Clegg, J.B., Weatherall, D.J.

Volltext

Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: A pilot study von Sulaiman Shoab, S, Porter, J.B, Scurr, J.H, Coleridge-Smith, P.D

Volltext

Deferasirox: An effective once-daily orally active iron chelator von Porter, John B

Volltext

Inhibition of iron-containing metalloenzymes by 3-hydroxypyridin-4-one chelators von Kayyali, R.S., Porter, J.B., Hider, R.C.

Volltext

Flow cytometric method for simultaneous assay of foetal haemoglobin containing red cells, reticulocytes and foetal haemoglobin containing reticulocytes: Flow Cytometry for F reticu... von Mundee, Y., Bigelow, N.C., Davis, B.H., Porter, J.B.

Volltext

Iron Mobilization From Hepatocyte Monolayer Cultures by Chelators: The Importance of Membrane Permeability and the Iron-Binding Constant von Porter, J.B., Gyparaki, M., Burke, L.C., Huehns, E.R., Sarpong, P., Saez, V., Hider, R.C.

Volltext

Enzyme inhibition by hydroxypyridinone iron chelators von Kayyali, R., Porter, J.B., Hider, R.C.

Volltext

Relative Oral Efficacy and Acute Toxicity of Hydroxypyridin-4-One Iron Chelators in Mice von Porter, J.B., Morgan, J., Hoyes, K.P., Burke, L.C., Huehns, E.R., Hider, R.C.

Volltext